골수 섬유증(MF) 시장 규모는 향후 몇 년 동안 꾸준히 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 개인 맞춤형 치료 접근법에 대한 수요 증가, 유전자 및 세포 치료에 대한 임상시험 증가, 병용 치료 사용 증가, 희귀 질환에 대한 의료 보장 확대, 혈액학 치료에 대한 투자 증가와 같은 요인에 기인할 수 있습니다. 이 기간에 예상되는 주요 트렌드로는 유전자 편집 기술의 발전, 섬유증 표적 치료제의 혁신, 차세대 JAK 억제제의 개발, 골수 섬유증에 대한 면역 치료의 관심 증가, 신약 개발에서 인공지능의 사용 확대 등이 있습니다.
표적 치료제에 대한 수요 증가는 골수 섬유증(MF) 시장의 성장을 견인할 것으로 예상됩니다. 표적 치료는 개인의 유전적, 환경적, 생활 습관적 요인에 따라 치료와 의료 결정을 맞춤화하는 접근 방식입니다. 이러한 치료법에 대한 수요 증가는 유전체학, 생명공학, 데이터 분석의 발전으로 더욱 정확하고 효과적이며 개인화된 치료가 가능해지면서 더욱 가속화되고 있습니다. 골수 섬유증은 JAK-STAT 신호와 같은 중요한 분자 경로를 강조함으로써 표적 치료법 개발의 핵심적인 예가 되고 있습니다. 이러한 경로를 통해 증상을 관리하고 질병의 진행을 늦추는 데 도움이 되는 JAK 억제제(룩소리티닙, 페드라티닙, 파크리티닙)와 같은 정밀 치료법을 설계할 수 있습니다. 예를 들어, 2024년 4월 미국 유전자 및 세포 치료학회는 임상 개발 중인 치료법의 수가 증가했으며, 1상 치료법이 2022년 4분기 이후 가장 높은 성장률인 11% 증가를 보이며 가장 큰 증가세를 보였다고 보고했습니다. 이에 따라 표적 치료제에 대한 수요 증가가 골수 섬유증 시장의 성장을 지속적으로 견인할 것으로 예상됩니다.
골수 섬유증 시장의 기업들은 치료 효과를 높이고 질병 진행을 억제하며 환자 예후를 개선하기 위해 표적 치료제를 확대하는 데 주력하고 있습니다. 예를 들어, JAK1/JAK2 억제제는 야누스 키나제 경로를 표적으로 하여 골수 섬유증의 염증과 비정상적인 혈구 생성을 감소시키고, ACVR1 억제제는 액티빈 수용체 유사 키나제 2(ALK2)를 차단하여 골수 섬유증과 질병 진행을 조절하는 역할을 합니다. 주목할 만한 사례로는 2023년 9월 영국에 본사를 둔 제약 회사인 GSK plc가 미국 식품의약국(FDA)으로부터 오자라(성분명 : 모멜로티닙)의 승인을 받은 것이 있습니다. 중등도 또는 고위험 골수 섬유증 환자를 위해 설계된 이 치료제는 JAK1/JAK2와 ACVR1을 모두 표적으로 하는 이중 작용 메커니즘을 가지고 있습니다. 염증 경로를 조절하고 헤모글로빈 수치를 개선하여 수혈의 필요성을 줄여줍니다. 이번 승인으로 치료 옵션이 확대되고 특히 빈혈로 고생하는 환자, 특히 질병 환경에서 중요한 미충족 수요가 있는 환자들을 위한 새로운 MF 관리 표준이 설정되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 골수 섬유증(MF) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 골수 섬유증(MF) 시장 : 성장률 분석
- 세계의 골수 섬유증(MF) 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 골수 섬유증(MF) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 골수 섬유증(MF) 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 골수 섬유증(MF) 시장 : 약물 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- JAK 억제제
- 면역 조절제
- 히드록시우레아
- 기타 약물의 유형
- 세계의 골수 섬유증(MF) 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 화학 치료
- 표적 치료
- 기타 치료의 유형
- 세계의 골수 섬유증(MF) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 비경구
- 기타 투여 경로
- 세계의 골수 섬유증(MF) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 온라인 약국
- 소매 약국
- 세계의 골수 섬유증(MF) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 홈케어
- 전문 클리닉
- 기타 최종 사용자
- 세계의 골수 섬유증(MF) 시장 : JAK 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 룩소리티닙
- 페드라티닙
- 모메로티닙
- 이타시티닙
- 세계의 골수 섬유증(MF) 시장 : 면역조절제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 탈리도마이드
- 레날리도미드
- 포말리도미드
- 세계의 골수 섬유증(MF) 시장 : 히드록시우레아 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구 히드록시우레아
- 주사용 히드록시우레아
- 세계의 골수 섬유증(MF) 시장 : 기타 약물 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 적혈구 조혈 자극 인자 제제(ESA)
- 다나졸
- 단일클론항체
- 화학 치료제
제7장 지역별 및 국가별 분석
- 세계의 골수 섬유증(MF) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 골수 섬유증(MF) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 골수 섬유증(MF) 시장 : 경쟁 구도
- 골수 섬유증(MF) 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bristol-Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc
- Eli Lilly and Company
- Gilead Sciences Inc.
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Incyte Corporation
- Sobi Inc.
- MorphoSys AG
- CTI BioPharma Corp.
- Suzhou Zelgen Biopharmaceutical Co. Ltd.
- NS Pharma Inc.
- Impact Biomedicines Inc.
- Kartos Therapeutics Inc.
- Geron Corporation
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 골수 섬유증(MF) 시장(2029년) : 새로운 기회를 제공하는 국가
- 골수 섬유증(MF) 시장(2029년) : 새로운 기회를 제공하는 부문
- 골수 섬유증(MF) 시장(2029년) : 성장 전략
제36장 부록
HBR
Myelofibrosis (MF) is a rare bone marrow disorder marked by the excessive formation of scar tissue, which impairs the normal production of blood cells. This condition can cause anemia, an enlarged spleen, and symptoms such as fatigue, night sweats, and bone pain.
The primary drug types used for treating myelofibrosis include JAK inhibitors, immunomodulators, hydroxyurea, and other therapies. JAK inhibitors are medications that block Janus kinase enzymes, which are involved in signaling pathways responsible for inflammation, immune response, and cell growth. These inhibitors are commonly used to treat conditions such as rheumatoid arthritis and myelofibrosis. Treatment options for MF include chemotherapy, targeted therapy, and other types of treatment. The medications can be administered orally, parenterally, or through other routes. They are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, with key end users including hospitals, home care settings, specialty clinics, and other healthcare facilities.
The myelofibrosis (MF) market research report is one of a series of new reports from The Business Research Company that provides myelofibrosis (MF) market statistics, including the myelofibrosis (MF) industry global market size, regional shares, competitors with the myelofibrosis (MF) market share, detailed myelofibrosis (MF) market segments, market trends, and opportunities, and any further data you may need to thrive in the myelofibrosis (MF) industry. This myelofibrosis (MF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The myelofibrosis (MF) market size has grown steadily in recent years. It will grow from $1.50 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of myeloproliferative neoplasms, greater awareness and earlier diagnosis, the growing adoption of JAK inhibitors, improved access to bone marrow transplants, and more regulatory approvals for new therapies.
The myelofibrosis (MF) market size is expected to see steady growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth during the forecast period can be attributed to factors such as the rising demand for personalized treatment approaches, an increase in clinical trials for gene and cell therapies, a growing use of combination therapies, expanding healthcare coverage for rare diseases, and increased investment in hematology care. Key trends expected in this period include advancements in gene-editing technologies, innovations in fibrosis-targeting drugs, the development of next-generation JAK inhibitors, growing interest in immunotherapy for myelofibrosis, and the expanding use of artificial intelligence in drug discovery.
The growing demand for targeted therapies is expected to drive the growth of the myelofibrosis (MF) market. Targeted therapies are an approach that tailors treatments and healthcare decisions based on an individual's genetic, environmental, and lifestyle factors. The increasing demand for these therapies is fueled by advancements in genomics, biotechnology, and data analytics, which allow for more precise, effective, and personalized treatments. Myelofibrosis serves as a key example in the development of targeted therapies by highlighting critical molecular pathways, such as JAK-STAT signaling. These pathways enable the design of precision treatments such as JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) that help manage symptoms and slow the progression of the disease. For instance, in April 2024, the American Society of Gene & Cell Therapy reported that the number of therapies in clinical development has grown, with Phase I therapies showing the most significant increase, rising by 11%-the highest growth rate since Q4 2022. As a result, the growing demand for targeted therapies is expected to continue driving growth in the myelofibrosis market.
Companies in the myelofibrosis market are focusing on expanding targeted therapies to enhance treatment efficacy, address disease progression, and improve patient outcomes. JAK1/JAK2 inhibitors, for example, target the Janus kinase pathway to reduce inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors block activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease progression. A notable example is in September 2023 when GSK plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Ojjaara (momelotinib). This treatment, designed for patients with intermediate- or high-risk myelofibrosis, has a dual mechanism of action that targets both JAK1/JAK2 and ACVR1. It helps regulate inflammatory pathways and improves hemoglobin levels, reducing the need for transfusions. This approval expands treatment options and sets a new standard in the management of MF, particularly for patients struggling with anemia, a significant unmet need in the disease landscape.
In February 2024, Novartis AG, a Swiss pharmaceutical company, acquired MorphoSys AG for EUR 2.7 billion ($2.91 billion). The acquisition enables Novartis to gain full ownership of pelabresib (CPI-0610), a promising treatment for myelofibrosis when combined with ruxolitinib, and tulmimetostat (CPI-0209), an investigational dual EZH1/EZH2 inhibitor being evaluated for solid tumors and lymphomas. This acquisition strengthens Novartis' oncology pipeline by adding innovative therapies aimed at addressing critical unmet medical needs in the field of oncology and myelofibrosis.
Major players in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation.
North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in myelofibrosis (MF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the myelofibrosis (MF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The myelofibrosis (MF) market consists of revenues earned by entities by providing services such as diagnostic services, patient support programs, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelofibrosis (MF) market also includes sales of hematological diagnostic tools, novel fibrosis-targeting drugs, and evolving regenerative therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Myelofibrosis (MF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on myelofibrosis (mf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for myelofibrosis (mf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelofibrosis (mf) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Jak Inhibitor; Immunomodulators; Hydroxyurea; Other Drug Types
- 2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
- 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
- 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
- Subsegments:
- 1) By Jak Inhibitor: Ruxolitinib; Fedratinib; Momelotinib; Itacitinib
- 2) By Immunomodulators: Thalidomide; Lenalidomide; Pomalidomide
- 3) By Hydroxyurea: Oral Hydroxyurea; Injectable Hydroxyurea
- 4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs); Danazol; Monoclonal Antibodies; Chemotherapy Agents
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Myelofibrosis (MF) Market Characteristics
3. Myelofibrosis (MF) Market Trends And Strategies
4. Myelofibrosis (MF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Myelofibrosis (MF) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Myelofibrosis (MF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Myelofibrosis (MF) Market Growth Rate Analysis
- 5.4. Global Myelofibrosis (MF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Myelofibrosis (MF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Myelofibrosis (MF) Total Addressable Market (TAM)
6. Myelofibrosis (MF) Market Segmentation
- 6.1. Global Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Jak Inhibitor
- Immunomodulators
- Hydroxyurea
- Other Drug Types
- 6.2. Global Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Targeted Therapy
- Other Treatment Types
- 6.3. Global Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes Of Administration
- 6.4. Global Myelofibrosis (MF) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.5. Global Myelofibrosis (MF) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
- 6.6. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Jak Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ruxolitinib
- Fedratinib
- Momelotinib
- Itacitinib
- 6.7. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Thalidomide
- Lenalidomide
- Pomalidomide
- 6.8. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Hydroxyurea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Hydroxyurea
- Injectable Hydroxyurea
- 6.9. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Erythropoiesis-Stimulating Agents (ESAs)
- Danazol
- Monoclonal Antibodies
- Chemotherapy Agents
7. Myelofibrosis (MF) Market Regional And Country Analysis
- 7.1. Global Myelofibrosis (MF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Myelofibrosis (MF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Myelofibrosis (MF) Market
- 8.1. Asia-Pacific Myelofibrosis (MF) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Myelofibrosis (MF) Market
- 9.1. China Myelofibrosis (MF) Market Overview
- 9.2. China Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Myelofibrosis (MF) Market
- 10.1. India Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Myelofibrosis (MF) Market
- 11.1. Japan Myelofibrosis (MF) Market Overview
- 11.2. Japan Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Myelofibrosis (MF) Market
- 12.1. Australia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Myelofibrosis (MF) Market
- 13.1. Indonesia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Myelofibrosis (MF) Market
- 14.1. South Korea Myelofibrosis (MF) Market Overview
- 14.2. South Korea Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Myelofibrosis (MF) Market
- 15.1. Western Europe Myelofibrosis (MF) Market Overview
- 15.2. Western Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Myelofibrosis (MF) Market
- 16.1. UK Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Myelofibrosis (MF) Market
- 17.1. Germany Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Myelofibrosis (MF) Market
- 18.1. France Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Myelofibrosis (MF) Market
- 19.1. Italy Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Myelofibrosis (MF) Market
- 20.1. Spain Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Myelofibrosis (MF) Market
- 21.1. Eastern Europe Myelofibrosis (MF) Market Overview
- 21.2. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Myelofibrosis (MF) Market
- 22.1. Russia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Myelofibrosis (MF) Market
- 23.1. North America Myelofibrosis (MF) Market Overview
- 23.2. North America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Myelofibrosis (MF) Market
- 24.1. USA Myelofibrosis (MF) Market Overview
- 24.2. USA Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Myelofibrosis (MF) Market
- 25.1. Canada Myelofibrosis (MF) Market Overview
- 25.2. Canada Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Myelofibrosis (MF) Market
- 26.1. South America Myelofibrosis (MF) Market Overview
- 26.2. South America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Myelofibrosis (MF) Market
- 27.1. Brazil Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Myelofibrosis (MF) Market
- 28.1. Middle East Myelofibrosis (MF) Market Overview
- 28.2. Middle East Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Myelofibrosis (MF) Market
- 29.1. Africa Myelofibrosis (MF) Market Overview
- 29.2. Africa Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Myelofibrosis (MF) Market Competitive Landscape And Company Profiles
- 30.1. Myelofibrosis (MF) Market Competitive Landscape
- 30.2. Myelofibrosis (MF) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Myelofibrosis (MF) Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. Novartis AG
- 31.3. GlaxoSmithKline plc
- 31.4. Eli Lilly and Company
- 31.5. Gilead Sciences Inc.
- 31.6. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
- 31.7. Incyte Corporation
- 31.8. Sobi Inc.
- 31.9. MorphoSys AG
- 31.10. CTI BioPharma Corp.
- 31.11. Suzhou Zelgen Biopharmaceutical Co. Ltd.
- 31.12. NS Pharma Inc.
- 31.13. Impact Biomedicines Inc.
- 31.14. Kartos Therapeutics Inc.
- 31.15. Geron Corporation
32. Global Myelofibrosis (MF) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Myelofibrosis (MF) Market
34. Recent Developments In The Myelofibrosis (MF) Market
35. Myelofibrosis (MF) Market High Potential Countries, Segments and Strategies
- 35.1 Myelofibrosis (MF) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Myelofibrosis (MF) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Myelofibrosis (MF) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
